Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. files periodic reports with the Securities and Exchange Commission as a publicly traded company listed on the New York Stock Exchange under ticker symbol BHC. The company also maintains a listing on the Toronto Stock Exchange. SEC filings provide detailed financial information, risk factors, business segment performance, and management discussion and analysis. Form 10-K annual reports offer comprehensive overviews of operations across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Quarterly Form 10-Q filings track financial performance throughout the fiscal year, breaking down revenue and profitability by therapeutic area and geographic region. Given the company's significant debt obligations, filings contain detailed disclosures regarding debt structure, maturity schedules, interest expenses, and refinancing activities. Form 8-K current reports disclose material events such as acquisitions, divestitures, executive changes, credit agreement amendments, and significant legal developments. Proxy statements (Form DEF 14A) provide information on corporate governance, executive compensation, board composition, and matters submitted for shareholder votes.
Patent litigation and intellectual property matters affecting key products like XIFAXAN receive disclosure in filings, as generic competition impacts future revenue streams. The company's relationship with Bausch + Lomb, in which it maintains a controlling interest, requires detailed segment reporting and potential disclosure of transactions between the entities. Regulatory compliance, manufacturing quality issues, and FDA enforcement actions would appear in SEC filings when material to investors. Debt covenant compliance, particularly given the company's leveraged capital structure, represents an important area of disclosure.
Investors use SEC filings to monitor trends in prescription volume, pricing dynamics, generic competition, research and development investments, and commercial strategy across therapeutic areas. Financial statements reveal capital allocation decisions, acquisition strategies, and operational efficiency across the diversified pharmaceutical portfolio. Risk factors sections outline threats including patent expirations, regulatory changes, reimbursement pressures, product liability, and competitive dynamics in pharmaceutical markets.
Bausch Health Companies Inc. (BHC) has launched exchange offers to swap its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to
Participation is limited to eligible institutional and non‑U.S. holders under U.S. and international securities laws, and acceptances will target a mix of approximately
Nomura Holdings filed an amended Schedule 13G reporting beneficial ownership of Bausch Health Companies Inc. common shares. Through wholly owned subsidiary Nomura Global Financial Products, Inc., the group reports beneficial ownership of 15,708,085 shares, representing 4.2% of the class.
The filing lists shared voting and dispositive power over 15,708,085 shares and no sole voting or dispositive power. The percentage is based on 370,473,221 shares outstanding as of September 30, 2025, as disclosed by the issuer. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Bausch Health Companies Inc. reported stronger Q3 2025 results. Revenue reached $2.681 billion versus $2.510 billion a year ago, and operating income rose to $619 million from $318 million. Net income attributable to Bausch Health was $179 million, compared with a loss of $85 million, translating to diluted EPS of $0.48.
For the first nine months, revenue was $7.470 billion and net income attributable to Bausch Health was $269 million with diluted EPS of $0.72. Operating cash flow was $905 million. Cash and cash equivalents were $1.308 billion, and total assets were $26.824 billion.
Debt and equity shifted due to refinancing: current portion of long-term debt decreased to $579 million from $2.674 billion, while non‑current long-term debt increased to $20.463 billion. Total equity improved to $356 million from a deficit of $(322) million at year‑end. The company acquired DURECT for $84 million, expensing $81 million as acquired IPR&D tied to Larsucosterol. Bausch + Lomb remained approximately 88% owned, and the company continues to evaluate completing the B+L separation.
Common shares outstanding were 370,516,926 as of October 24, 2025.
Amendment corrects previously reported insider holdings. This Form 4/A updates an earlier filing to state that John Paulson indirectly beneficially owned 70,755,869 common shares of Bausch Health Companies Inc. as of the 09/30/2025 transaction date. The amendment says the corrected amount matches what was reported on a prior Form 4 filed 08/14/2025 and attributes the holdings to funds managed by Paulson Capital Inc., while the reporting person disclaims direct beneficial ownership except for any pecuniary interest. The filing was signed by an attorney-in-fact on 10/06/2025.
John Paulson, a director of Bausch Health Companies Inc. (BHC), received 9,689 restricted share units on 09/30/2025 as compensation for board service for the quarter ended that date; each unit vests into one common share. After the grant, Mr. Paulson directly beneficially owns 351,128 common shares. In addition, he may be deemed an indirect beneficial owner of 32,791,702 common shares held by investment funds managed by Paulson Capital Inc., although the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The transaction was reported on Form 4 and signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies director Sandra Leung was granted 3,673 restricted share units (RSUs) issued in lieu of cash compensation for her service on the board for the quarter ending September 30, 2025. Each RSU represents a contingent right to receive one common share. After the award, the reporting person beneficially owned 33,822 common shares. The transaction was reported on a Form 4 and executed under transaction code V, with the RSUs recorded at $0 price as issued units rather than an open-market purchase.
Bausch Health Companies Inc. director Amy B. Wechsler received 1,065 restricted share units on 09/30/2025 issued in lieu of cash compensation for board service. Each restricted share unit represents a contingent right to one common share and was reported as having a $0 cash price. After the grant, the reporting person beneficially owned 265,452 common shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies Inc. disclosed a contractual mechanism tied to the company’s transaction with DURECT Corporation that grants each share a non-transferable contingent value right (CVR). The CVR represents the holder’s pro rata claim on two milestone payments that together can total up to
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
